(Q46003084)

18 December 2017

title

Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? (English)

1 reference

18 December 2017

main subject

4β-hydroxycholesterol

1 reference

ChEBI release 2020-05-28

D Tomalik-Scharte

1

1 reference

18 December 2017

D Lütjohann

2

1 reference

18 December 2017

O Doroshyenko

3

1 reference

18 December 2017

D Frank

4

1 reference

18 December 2017

A Jetter

5

1 reference

18 December 2017

U Fuhr

6

1 reference

18 December 2017

language of work or name

English

0 references

publication date

20 May 2009

1 reference

18 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

18 December 2017

volume

86

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

147-153

1 reference

18 December 2017

https://scigraph.springernature.com/pub.10.1038/clpt.2009.72

exact match

0 references

cites work

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Metabolism and elimination of quinine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Metabolism of 4 beta -hydroxycholesterol in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Physiologic and temporal variation in hepatic elimination of midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Chronopharmacokinetic study with prolonged infusion of midazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.72

21 January 2018

Identifiers

DOI

10.1038/CLPT.2009.72

1 reference

18 December 2017

Dimensions Publication ID

1041268147

0 references

1 reference

18 December 2017